Nanexa AB - Home

Where Nanoengineering
Meets Drug Delivery

Nanexa’s PharmaShell® technology is transforming the face of long-acting ’super generic’ drugs with its proprietary suite of Atomic Layer Deposition (ALD) technologies.
PharmaShell formulations will allow indications including type 2 diabetes/obesity, cancers, cardiovascular and psychiatric disorders to be treated with monthly injections.

PRESSRELEASES

6 November, 2025

Nanexa publishes interim report for January-September 2025

We have progressed with the optimization of our GLP-1 formulations, extended an existing commercial partnership, received approval for a PharmaShell patent application in Japan and submitted three new patent applications.

16 October, 2025

Nanexa named as finalist in Fierce Innovation Awards Life Sciences Edition 2025

Nanexa, is pleased to announce that the company has been selected as a finalist in the Drug Delivery Technology category by the renowned industry publication Fierce Life Sciences. The annual Fierce Life Sciences Innovation Awards identify and showcase outstanding innovation that is driving improvements in life science technologies. Their panel of expert judges has identified Nanexa as a company whose pioneering solutions have the potential to create efficiencies, engage patients, or revolutionize the pharmaceutical industry.